Saffron Extract Dosage Guide — Clinical Doses by Application

01 · Quick reference

Saffron Extract Dosage at a Glance

The range is not one-size-fits-all. The table covers six frequently searched applications; all values are human-study doses, not suggested self-treatment protocols. Unless expressly marked otherwise, a dose refers to a saffron preparation rather than purified crocin. Trials differ in their botanical starting material and chemical standardization, so the numbers are not necessarily comparable across rows.

Reading rule: look at the preparation, population and endpoint before borrowing a number for a formula. The separate crocin study in the eye-health row is deliberately identified as an isolated-compound trial.

If you want a broader overview of outcomes rather than dosage alone, our saffron extract benefits guide reviews the evidence across applications. Here, the focus is narrower: the actual human-study dose, preparation and formulation implications.

02 · Clinical evidence

Clinically Studied Doses by Application

For a product developer, the dose is only the beginning of a study record. The useful questions are: who took it, what formulation was used, when were outcomes measured, and was the main trial outcome different from placebo? The evidence below emphasizes those details rather than assigning one “optimal” number to each health category.

Saffron Extract Dosage for Mood and Stress

In a 2017 randomized trial of 128 adults reporting low mood, the proprietary stigma extract affron® was tested at 22 mg and 28 mg daily for four weeks. The 28 mg arm improved the primary mood-disturbance measure versus placebo; the 22 mg arm did not show a treatment effect. This is a useful warning against assuming that any smaller amount will work simply because it is still measured in milligrams.^[1]

A larger Australian trial published in 2025 enrolled 202 adults with subclinical depressive symptoms and studied 28 mg/day for 12 weeks. Its primary depression measure improved more than placebo (Cohen’s d = 0.39), but the majority of secondary outcomes did not show significant between-group differences. A separate 2025 placebo-controlled trial enrolled 51 adults and used 30 mg/day for six weeks; it did not meet its primary composite outcome for depression, anxiety and fatigue. These are not mutually exclusive findings: they tested different preparations and endpoints in different populations.^[2][3]

For a closer examination of depression-specific meta-analyses, effect sizes and antidepressant comparators, see our saffron extract for depression research review. Those disease-focused comparisons need more context than a multi-application dosage table can provide.

Saffron Extract Dosage for Sleep Quality

Sleep is one of the clearest examples of why both total daily dose and timing belong in a dosage guide. A 2020 randomized trial gave 63 adults affron® at 14 mg twice daily (28 mg/day) over 28 days. A 2021 multi-dose trial in 120 adults compared 14 mg/day and 28 mg/day, administered approximately one hour before bedtime, over 28 days. Both belong to the clinical record, but they should not be described as the same schedule.^[4][5]

A 2025 randomized trial recruited 165 adults with moderate insomnia to receive Safr’Inside™ 20 mg/day, 30 mg/day or placebo for four weeks, roughly 60 minutes before bed. In the main analysis, the combined saffron groups improved the primary Athens Insomnia Scale measure more than placebo; both individual saffron groups also improved a secondary self-reported sleep-quality measure at weeks three and four. The study did not establish that 30 mg was uniformly better than 20 mg.^[6]

Another six-week trial used 15.5 mg/day of a specific Saffr’activ® formulated ingredient. Its paper distinguishes the finished ingredient weight from the smaller amount of dry saffron extract and specified crocins/safranal within it. That extra ingredient-level information is exactly what should be preserved when a formulator compares suppliers.^[7]

Saffron Dosage for Eye Health

Eye-health studies are not general wellness trials. They mainly involve patients with age-related macular degeneration (AMD) or diabetic macular disease, and outcome measures may include electroretinography, best-corrected visual acuity or macular thickness. A crossover trial of 100 adults with mild-to-moderate AMD tested saffron 20 mg/day for three months against placebo, followed by crossover. Another randomized AMD trial used 30 mg/day for six months and reported some retinal-function benefits at three months that did not persist across every measurement at six months. A separate 54-person study tested 50 mg/day for three months, but its smaller design does not create a universal 50 mg recommendation.^[8][9][10]

A different 2018 trial studied isolated crocin tablets at 5 mg or 15 mg/day in 60 patients with refractory diabetic maculopathy. The 15 mg crocin arm improved selected measured outcomes relative to placebo, while the 5 mg arm did not demonstrate statistically significant differences. This is crocin dose evidence, not evidence for a 15 mg daily dose of an ordinary 3% saffron extract.^[11]

Saffron Dosage for Cognitive Function

The often-cited cognitive dose of 30 mg/day comes principally from trials in Alzheimer's disease rather than healthy adults seeking sharper memory. A 16-week double-blind randomized study involving 46 patients compared saffron 15 mg twice daily with placebo and found better results on clinical cognitive assessments. A 22-week study of 54 patients compared the same daily saffron quantity with donepezil. The study reported no significant between-group difference on its major clinical measures, but that result does not establish equivalence or justify replacing a prescribed medicine.^[12][13]

For a healthy-cognition supplement, this evidence is better described as research in a disease-specific population. The available studies do not justify claiming that 30 mg/day prevents dementia or reliably improves memory in healthy adults.

Saffron Extract Dosage for PMS and PMDD

In the foundational 2008 PMS study, women received 30 mg/day as 15 mg in the morning and 15 mg in the evening for two menstrual cycles. Symptom and related mood scores improved compared with placebo. The regimen was continuous through the cycles, not confined to the days just before menstruation.^[14]

A later randomized PMDD study evaluated 15 mg twice daily during the luteal phase for two cycles. The saffron group improved more than placebo on the Daily Record of Severity of Problems, although another assessed mood scale did not show the same group separation. PMS and premenstrual dysphoric disorder are different clinical populations; a label or formulation brief should not flatten their trial schedules into one instruction.^[15]

Saffron Dosage for Weight Management and Snacking

The number that surprises most readers is 176.5 mg/day. That was the daily amount of the specific Satiereal saffron-stigma preparation investigated in an eight-week placebo-controlled study of 60 mildly overweight women. Researchers reported reduced snacking and a modest difference in body weight. It does not follow that 176.5 mg of every saffron extract works similarly, nor that a high-crocin grade can be substituted at a lower amount.^[16]

A separate 2018 study in 84 patients with coronary artery disease compared 30 mg/day saffron aqueous extract, 30 mg/day isolated crocin, and placebo over eight weeks. Both active arms produced changes in appetite or dietary-intake measures; the interventions are chemically different even though the labelled weight was identical.^[17]

Broader research is less dramatic than individual product headlines. A September 2026 meta-analysis of 28 trials and 1,623 participants reported average changes of −1.09 kg body weight, −0.39 kg/m² BMI and −1.14 cm waist circumference. These pooled changes were statistically significant but modest, and the varied interventions cannot define one reliable saffron-extract weight-management dose.^[18]

03 · Research detail

The Clinical Dose Matrix: What Was Actually Tested?

The first table answers “how much?”; this second table answers “how comparable?”. It separates extracted saffron from isolated crocin, preserves the administration schedule, and includes studies with mixed or nonsignificant outcomes. That distinction is more useful to a formulation team than a list of supposedly effective doses alone.

The table is a selected research reference, not a systematic review of every saffron trial. “Not reported” standardization should never be silently filled in using the composition of a different supplier’s extract.

04 · Timing

When to Take Saffron Extract — and for How Long?

There is no single clinically established “best time of day” for all uses. Sleep research includes an evening dose approximately one hour before bedtime, while mood and PMS studies have often used divided morning-and-evening doses. The two schedules cannot be ranked without a direct comparison of the same formulation and outcome.

With food or on an empty stomach? This has not been resolved by head-to-head absorption or efficacy trials across saffron products. In one eight-week 30 mg/day mood study, participants took one capsule in the morning and one in the evening, at least 30 minutes after a meal.^[24] That is a documented study instruction, not evidence that taking saffron after meals is superior for all uses.

Study duration should also not be mistaken for the minimum time needed to feel an effect. If a protocol measured its primary outcome at week six, that does not prove nothing happens before week six. Likewise, an improvement in a questionnaire at week three does not guarantee each user will notice a difference at that point.

05 · Dose comparison

Why Do Saffron Extract Doses Range from 28 to 176.5 mg?

Four figures circulate widely online: 28 mg, 30 mg, 88.5 mg and 176.5 mg. They are not four tiers of potency. The first two recur in clinical protocols for certain standardized extracts. The other figures are often encountered in commercial supplement labels and the specific Satiereal snacking trial. The question is not which number is largest; it is what ingredient each number represents.

Even when two products declare the same crocin percentage, their extraction method, botanical part, carrier and additional constituents may differ. A percentage can help calculate ingredient mass; it cannot prove that the products behave alike in people. In particular, do not reduce a 176.5 mg patented extract to a smaller high-crocin quantity using a single marker alone.

06 · Standardization

Saffron Extract vs. Crocin: How to Read the Dosage

“Saffron extract” describes a botanical preparation. “Crocin” may refer to an individual compound, while “crocins” often describes a family of related carotenoid glycosides. “Safranal” is another distinct saffron constituent. A certificate reading 3% crocin does not tell you whether the assay quantifies one reference compound or a defined sum of crocin isomers unless the analytical method and calculation basis are provided.

Botanical source is a separate identity question. Saffron stigma and gardenia fruit can both provide crocin-type compounds, so a crocin percentage alone does not authenticate a material as Crocus sativus. For the analytical and sourcing differences, see our saffron extract vs. gardenia extract comparison. In a saffron-labeled ingredient, chromatographic fingerprinting and a suitable marker panel are more informative than color intensity alone.^[26]

That analytical detail is not theoretical. Published comparisons of UV–visible and HPLC-DAD methods found that spectrophotometric measurements of safranal could be overestimated by interference from other saffron compounds. A COA reporting an apparently similar percentage using another method may therefore not be an apples-to-apples match.^[20]

What Did the Clinical Brands Actually Standardize?

Three human-trial preparations make the limitation of an extract-only dose especially clear. The entries below describe the specific products and analytical methods reported in those papers; they are not specifications that can be carried across to every lot, year or competing supplier.

A reported “greater than” percentage is a lower specification threshold, not a precise lot assay. These marker figures cannot be used to infer the complete composition, bioavailability or efficacy of a generic extract.

What Does 3%, 5% or 10% Crocin Deliver?

The arithmetic is straightforward: labelled crocin (mg) = saffron extract (mg) × declared crocin fraction. The numbers below are calculated from the stated percentages; they are not clinical equivalence claims.

A useful counterexample comes from the 2018 diabetic-maculopathy study: its 15 mg/day isolated crocin arm supplied 15 mg of the studied compound. At a purely numerical level, matching that mass with an extract declared as 3% crocin would mean 500 mg of extract. That is not an evidence-based substitution: the extract would include many other constituents, and its absorption, tolerability and effect have not been established by that mathematical conversion.^[11]

07 · Capsule formulation

From a Clinical Dose to a Capsule-Fill Formula

The most useful formulation lesson is that daily extract dose, marker content and total capsule fill weight are three separate quantities. A clinical paper may disclose all three, two of them, or only the first. Do not calculate one by assuming the others.

A Real Clinical Capsule Example, Not a Hypothetical Formula

In the randomized trial by Jackson and colleagues (published in 2021), participants received 30 mg/day of a Safr’Inside™ extract over eight weeks. Each active capsule contained 15 mg saffron extract plus 345 mg maltodextrin, giving 360 mg of combined powder per capsule and 30 mg extract across two capsules per day. This is an unusually useful example because the paper specifies both the botanical-ingredient mass and the carrier. The primary total-mood-disturbance outcome was not statistically significant, although some secondary findings differed between groups. A real capsule formula is evidence of how the study material was administered, not automatic proof of clinical efficacy.^[24]

A 2025 trial provides a useful second comparison: each hard-shell capsule contained 370 mg powder including 15 mg saffron extract; participants received two capsules per day, for 30 mg/day of extract. The paper did not provide a breakdown of all 355 mg of non-extract powder as separate percentages. Two clinical studies therefore used the same 15 mg botanical amount per capsule but different total powder fills (360 vs. 370 mg). That difference reflects the dosage form, not a ten-milligram difference in saffron dose.^[3]

For your own prototype, the numbers below show raw-material arithmetic. They do not establish the clinically effective dose of the selected generic extract or the final size of the capsule. Real capsule-shell selection depends on packed density, flow and validated filling performance.

There is a second, less obvious calculation that formulators often ask for: what mass of a higher-grade extract would deliver the same labelled crocin mass? A 30 mg capsule of 3% extract provides a theoretical 0.9 mg crocin; 9 mg of a 10% extract also contains a theoretical 0.9 mg. Those are marker-mass equivalents only. They are not demonstrated clinical substitutes, because other components and the tested material may be different.

From Ten Capsules to a Production Purchase Quantity

For a prototype containing 30 mg saffron extract per capsule, 10,000 capsules require 300 g of extract in the finished units; 100,000 capsules require 3.0 kg. At a hypothetical 98% manufacturing yield, the 10,000-capsule batch would need about 306.1 g at issue to supply 300 g in accepted capsules, assuming the losses affect material proportionally. This is a production-planning illustration, not permission to change the declared per-capsule dose or an estimate of your plant’s actual yield.

Cost-per-1,000-capsules can be budgeted as 0.03 × your extract price per kilogram in this 30 mg/capsule example, before blending, excipients, shell, QC, freight and wastage. It is a useful procurement figure precisely because it keeps the studied-dose question separate from the raw-material economics.

For production, ask the supplier about the botanical part, extraction route, marker definition, method of analysis, excipients, batch-to-batch range, microbiology, contaminants and stability. At low active fill weights, powder mixing and dose uniformity deserve particular attention. A tidy conversion spreadsheet is useful, but it cannot replace a validated formulation.

08 · Safety & boundaries

Safety, Drug Interactions and the Limits of Dose Evidence

Saffron is a familiar culinary spice, but concentrated extracts used in clinical trials are not equivalent to occasional food use. A 2026 systematic safety review examining 102 clinical trials and one case report estimated adverse events at around 17.5% across the relevant recorded exposures; the most commonly reported problems were gastrointestinal and generally minor. The authors also stressed inconsistent reporting, limited long-term evidence and additional caution with higher doses or prolonged use.^[19]

Pregnancy and breastfeeding warrant particular caution; supplement-dose safety in these populations is not established. People taking antidepressants, anticoagulants or antiplatelet drugs, as well as those managing psychiatric or medical conditions, should obtain individual medical advice before adding saffron supplements. Do not change prescribed treatment on the basis of a comparative saffron study. Drug-interaction uncertainty is not evidence that interactions cannot occur.

For U.S. dietary supplements, clinical research discussing depression, Alzheimer’s disease or macular degeneration does not authorize claims that the finished product treats these diseases. FDA distinguishes permissible substantiated structure/function claims from unauthorized disease claims; other markets impose their own requirements.^[22]

FAQ

Frequently Asked Questions

For formulators

Choosing a Saffron Extract for Your Formulation

If your purpose is early-stage supplement development, start by selecting a study that matches the intended use and population. Record the specific material and administration protocol before estimating ingredient cost per serving. Next, compare candidate suppliers on a defined crocin/crocins assay rather than a percentage quoted without a test method. Finally, account for stability, microbial and contaminant specifications, declared carriers, and manufacturing yield in your capsule prototype.

Authenticity belongs beside potency. A strong candidate COA should define the assay reference standard, identify the raw botanical source and state whether the test covers one crocin isomer or a sum. For material sold specifically as saffron stigma extract, an HPLC/LC-MS fingerprint and appropriate botanical identity checks can help identify substitutions; gardenia-associated markers such as geniposide are useful in investigations where the raw-material history raises concern.^[26] No single compound test should be presented as a complete authentication guarantee.

Research transfer requires a paper trail. Record the intended market, adult target population, proposed serving weight, chosen primary study, tested extraction type, analytical comparability, and what remains unverified. Industry-funded studies can still be useful, but independent replication, preregistered outcomes and differences between primary and secondary endpoints deserve explicit attention before a label claim is finalized.

The result should be a technical decision that can be defended in a product development file: we chose this material at this formulation amount because its assay, quality controls and intended application are documented — not because a different brand conducted a promising trial at the same number of milligrams.

Request COA & SampleView Saffron Extract Specifications

References

Clinical Studies and Source Notes

Research approach: priority was given to human randomized trials and their published study methods for dose, frequency, duration and outcome. Systematic reviews were used to contextualize mixed evidence. References are selected to make each major figure auditable; this page is not a formal systematic review, and ingredient standardization is not inferred when a paper does not adequately report it.

Mood and sleep

[1] Lopresti AL et al. 2017. affron®, a novel saffron extract, improves mood in healthy adults over four weeks. Complement Ther Med. PMID 28735826.

[2] Lopresti AL et al. 2025. An Examination into the Effects of a Saffron Extract (Affron) on Mood and General Wellbeing in Adults Experiencing Low Mood. J Nutr. PMID 40414301.

[3] Amadieu C et al. 2025. Effect of saffron extract supplementation on mood in healthy adults with subclinical symptoms of depression. Am J Clin Nutr. Full study and capsule methods; PMID 41047129.

[4] Lopresti AL et al. 2020. Effects of saffron on sleep quality in healthy adults with self-reported poor sleep. J Clin Sleep Med. PMID 32056539.

[5] Lopresti AL et al. 2021. An investigation into an evening intake of a saffron extract (affron®) on sleep quality, cortisol, and melatonin concentrations. Sleep Med. PMID 34438361.

[6] Schuster J et al. 2025. Effect of a saffron extract on sleep quality in adults with moderate insomnia. Sleep Med X. Full study, PMCID PMC12281372.

[7] Pachikian BD et al. 2021. Effects of Saffron Extract on Sleep Quality: A Randomized Double-Blind Controlled Clinical Trial. Nutrients. Full study, PMCID PMC8145009.

Eye, cognition and menstrual health

[8] Broadhead GK et al. 2019. Saffron therapy for the treatment of mild/moderate age-related macular degeneration: a randomised clinical trial. Graefes Arch Clin Exp Ophthalmol. PMID 30343354.

[9] Lashay A et al. 2016/2017. Short-term Outcomes of Saffron Supplementation in Patients with Age-related Macular Degeneration. Full study, PMCID PMC5342880.

[10] Riazi A et al. 2017. The impact of saffron supplementation on visual function in patients with dry age-related macular degeneration. Italian Journal of Medicine. DOI 10.4081/itjm.2016.758.

[11] Sepahi S et al. 2018. Effects of Crocin on Diabetic Maculopathy: A Placebo-Controlled Randomized Clinical Trial. Am J Ophthalmol. PMID 29550187.

[12] Akhondzadeh S et al. 2010. Saffron in the treatment of patients with mild to moderate Alzheimer's disease: a 16-week randomized trial. J Clin Pharm Ther. PMID 20831681.

[13] Akhondzadeh S et al. 2010. A 22-week, multicenter, randomized controlled trial of Crocus sativus in mild-to-moderate Alzheimer's disease. Psychopharmacology. PMID 19838862.

[14] Agha-Hosseini M et al. 2008. Crocus sativus L. (saffron) in the treatment of premenstrual syndrome. BJOG. PMID 18271889.

[15] Rajabi F et al. 2020/2021. Saffron for the Management of Premenstrual Dysphoric Disorder: A Randomized Controlled Trial. PMID 33457343.

Weight, chemistry and safety

[16] Gout B et al. 2010. Satiereal, a Crocus sativus L. extract, reduces snacking and increases satiety in mildly overweight women. Nutr Res. PMID 20579522.

[17] 2018 randomized trial. Saffron and crocin improved appetite, dietary intakes and body composition in patients with coronary artery disease. Full study, PMCID PMC5787332.

[18] Vazirinasab A et al. 2026. Effects of saffron supplementation on obesity indices: a systematic review and dose–response meta-analysis of randomized controlled trials. Nutr Metab. DOI 10.1186/s12986-026-01207-z.

[19] 2026 systematic review. Adverse Events of Saffron (Crocus sativus L.): Systematic Review of Current Evidence. Health Sci Rep. Full review, PMCID PMC13121846.

[20] García-Rodríguez MV et al. 2017. Comparative evaluation of an ISO 3632 method and an HPLC-DAD method for safranal quantity determination in saffron. Food Chem. PMID 27979282.

[21] Almodóvar P et al. 2020. Bioaccessibility and Pharmacokinetics of a Commercial Saffron (Crocus sativus L.) Extract. Full study, PMCID PMC7013346.

[22] U.S. Food and Drug Administration. Structure/Function Claims, Dietary Supplements. FDA guidance.

[23] NIH Office of Dietary Supplements. Saffron 88.5 mg, Dietary Supplement Label Database. Manufacturer-reported marketed label data, not efficacy confirmation. DSLD ID 338581.

[24] Jackson PA et al. 2021. Effects of Saffron Extract Supplementation on Mood, Well-Being, and Response to a Psychosocial Stressor in Healthy Adults: A Randomized, Double-Blind, Parallel Group, Clinical Trial. Front Nutr. 7:606124. Full text and capsule composition; PMID 33598475.

Standardization and identity

[25] Lopresti AL et al. 2026. The effects of a saffron extract (Affron®) on mood, sleep, self-esteem, and exploratory measures in women aged 50 to 70 years. Front Nutr. Full study with extract composition.

[26] Non-targeted metabolomics and chemometrics for saffron (Crocus sativus L.) authentication and adulteration detection. Analytical study identifying gardenia-associated markers including geniposide, shanzhiside and jasminosides. Original research.